Our new findings, made in 2 separate patient cohorts, that additional autoantibody specificities in anti–TIF1-γ–positive patients are associated with a low incidence of cancer (anti-CCAR1, -TBLX1R1, -IMMT, and -CIZ1), will find rapid application in improved risk stratification to guide clinical evaluations in newly diagnosed DM. The gene discussed is TRIM33; the disease is cancer.